Literature DB >> 19651122

Pro-angiogenic properties of orosomucoid (ORM).

Ster Irmak1, Leticia Oliveira-Ferrer, Bernhard B Singer, Süleyman Ergün, Derya Tilki.   

Abstract

The acute phase protein orosomucoid (ORM), also known as alpha1-acid glycoprotein (AGP), is found to be increased in infection, inflammation and cancer. Recently, we demonstrated that ORM is produced by endothelial cells and detectable in urine samples of patients with bladder cancer. However, it was not clarified yet whether ORM plays a role in new vessel formation. To this aim we performed overexpression and gene silencing for ORM in human microvascular endothelial cells (HDMECs). ORM purified from human plasma was used individually or in combination with VEGF-A in endothelial tube formation, migration and proliferation assay. The in vivo effect of ORM in angiogenesis was studied using the chicken chorionallantois membrane (CAM) with subsequent counting of blood vessels on histological sections from the stimulated areas of CAM tissue. Our data show that ORM alone enhances migration but not proliferation of HDMECs. ORM alone does not induce endothelial tubes in vitro but simultaneous application of ORM with VEGF-A increases the number and the network of VEGF-A-induced endothelial tubes. Remarkably, ORM alone induces new vessel formation in vivo using CAM assay and supports the VEGF-A-induced new vessel formation in this assay. Taken together, our results let assume that ORM has pro-angiogenic properties and supports the angiogenic effect of VEGF-A. Thus, ORM seems to be involved in the regulation of angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19651122     DOI: 10.1016/j.yexcr.2009.07.024

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  10 in total

1.  Integrative Multi-omics Analysis to Characterize Human Brain Ischemia.

Authors:  Laura Ramiro; Teresa García-Berrocoso; Ferran Briansó; Leire Goicoechea; Alba Simats; Víctor Llombart; Ricardo Gonzalo; Alexandre Hainard; Elena Martínez-Saez; Francesc Canals; Jean-Charles Sanchez; Alex Sánchez-Pla; Joan Montaner
Journal:  Mol Neurobiol       Date:  2021-05-03       Impact factor: 5.590

2.  Orosomucoid 2 inhibits tumor metastasis and is upregulated by CCAAT/enhancer binding protein β in hepatocellular carcinomas.

Authors:  Tao Fang; Meiling Cui; Ji Sun; Chao Ge; Fangyu Zhao; Lin Zhang; Hua Tian; Lixing Zhang; Taoyang Chen; Guoping Jiang; Haiyang Xie; Ying Cui; Ming Yao; Hong Li; Jinjun Li
Journal:  Oncotarget       Date:  2015-06-30

3.  Abundant proteins in platelet-rich fibrin and their potential contribution to wound healing: An explorative proteomics study and review of the literature.

Authors:  Emre Yaprak; Murat Kasap; Gurler Akpinar; Eylul Ece Islek; Alper Sinanoglu
Journal:  J Dent Sci       Date:  2018-09-03       Impact factor: 2.080

4.  Comparison of orosomucoid-1 immunoexpression and angiogenesis between oral squamous cell carcinoma cases with different histological grades.

Authors:  Celeste Sánchez-Romero; Ronell Bologna-Molina; Rogelio González-González; Sirced Salazar-Rodríguez; Nataly Barreiro Mendoza
Journal:  J Oral Maxillofac Pathol       Date:  2021-08-31

5.  Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selection.

Authors:  Fiona Collinson; Michelle Hutchinson; Rachel A Craven; David A Cairns; Alexandre Zougman; Tobias C Wind; Narinder Gahir; Michael P Messenger; Sharon Jackson; Douglas Thompson; Cybil Adusei; Jonathan A Ledermann; Geoffrey Hall; Gordon C Jayson; Peter J Selby; Rosamonde E Banks
Journal:  Clin Cancer Res       Date:  2013-08-09       Impact factor: 12.531

6.  Comparative systems pharmacology of HIF stabilization in the prevention of retinopathy of prematurity.

Authors:  George Hoppe; Suzy Yoon; Banu Gopalan; Alexandria R Savage; Rebecca Brown; Kelsey Case; Amit Vasanji; E Ricky Chan; Randi B Silver; Jonathan E Sears
Journal:  Proc Natl Acad Sci U S A       Date:  2016-04-18       Impact factor: 11.205

7.  The orosomucoid 1 protein (α1 acid glycoprotein) is overexpressed in odontogenic myxoma.

Authors:  Alejandro García-Muñoz; Mario A Rodríguez; Ronell Bologna-Molina; Febe E Cázares-Raga; Fidel C Hernández-Hernández; J Eduardo Farfán-Morales; Juan J Trujillo; Carlos Licéaga-Escalera; Guillermo Mendoza-Hernández
Journal:  Proteome Sci       Date:  2012-08-13       Impact factor: 2.480

8.  The acute phase reactant orosomucoid-1 is a bimodal regulator of angiogenesis with time- and context-dependent inhibitory and stimulatory properties.

Authors:  Giovanni Ligresti; Alfred C Aplin; Bruce E Dunn; Ann Morishita; Roberto F Nicosia
Journal:  PLoS One       Date:  2012-08-14       Impact factor: 3.240

9.  Orosomucoid-1 Expression in Ameloblastoma Variants.

Authors:  Alejandro García-Muñoz; Ronell Bologna-Molina; Mario A Rodríguez; Rodrigo Liceága-Reyes; Jose Eduardo Farfán-Morales; Saray Aranda-Romo; Nelly Molina-Frechero; Rogelio González-González
Journal:  Int J Mol Cell Med       Date:  2016

10.  Integrated GWAS and Gene Expression Suggest ORM1 as a Potential Regulator of Plasma Levels of Cell-Free DNA and Thrombosis Risk.

Authors:  Sonia Lopez; Angel Martinez-Perez; Alba Rodriguez-Rius; Ana Viñuela; Andrew A Brown; Laura Martin-Fernandez; Noelia Vilalta; Marc Arús; Nikolaos I Panousis; Alfonso Buil; Maria Sabater-Lleal; Juan Carlos Souto; Emmanouil T Dermitzakis; Jose Manuel Soria
Journal:  Thromb Haemost       Date:  2022-03-10       Impact factor: 6.681

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.